SI2148681T1 - Selektivni modulatorji progesterona v zdravljenju maternične krvavitve - Google Patents

Selektivni modulatorji progesterona v zdravljenju maternične krvavitve

Info

Publication number
SI2148681T1
SI2148681T1 SI200831629A SI200831629A SI2148681T1 SI 2148681 T1 SI2148681 T1 SI 2148681T1 SI 200831629 A SI200831629 A SI 200831629A SI 200831629 A SI200831629 A SI 200831629A SI 2148681 T1 SI2148681 T1 SI 2148681T1
Authority
SI
Slovenia
Prior art keywords
modulators
treatment
uterine bleeding
selective progesterone
progesterone
Prior art date
Application number
SI200831629A
Other languages
English (en)
Inventor
Bartholomeus C. J. M. Fauser
Ernest Loumaye
Original Assignee
Preglem S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem S.A. filed Critical Preglem S.A.
Publication of SI2148681T1 publication Critical patent/SI2148681T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
SI200831629A 2007-04-20 2008-04-18 Selektivni modulatorji progesterona v zdravljenju maternične krvavitve SI2148681T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90787507P 2007-04-20 2007-04-20
PCT/IB2008/000945 WO2008129396A2 (en) 2007-04-20 2008-04-18 Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
EP08737471.6A EP2148681B1 (en) 2007-04-20 2008-04-18 Selective progesterone modulators in the treatment of uterine bleeding

Publications (1)

Publication Number Publication Date
SI2148681T1 true SI2148681T1 (sl) 2016-07-29

Family

ID=39766931

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831629A SI2148681T1 (sl) 2007-04-20 2008-04-18 Selektivni modulatorji progesterona v zdravljenju maternične krvavitve

Country Status (13)

Country Link
US (2) US8569274B2 (sl)
EP (1) EP2148681B1 (sl)
JP (2) JP5785392B2 (sl)
CA (1) CA2684450C (sl)
CY (1) CY1117586T1 (sl)
DK (1) DK2148681T3 (sl)
ES (1) ES2575554T3 (sl)
HR (1) HRP20160689T1 (sl)
HU (1) HUE029397T2 (sl)
PL (1) PL2148681T3 (sl)
PT (1) PT2148681E (sl)
SI (1) SI2148681T1 (sl)
WO (1) WO2008129396A2 (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TW201002736A (en) * 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
KR102166867B1 (ko) * 2010-03-22 2020-10-19 앨러간 파마슈티컬스 인터내셔널 리미티드 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2013181449A1 (en) 2012-05-31 2013-12-05 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP2931251A1 (en) * 2012-12-14 2015-10-21 Laboratoire HRA Pharma Copper intrauterine device
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
JP2017523138A (ja) 2014-07-29 2017-08-17 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 経皮クリーム
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3394078A4 (en) 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. GLUCOCORTICOID RECEPTOR INHIBITORS
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
AU714959B2 (en) * 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
DE602005026290D1 (de) * 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
CA2585334C (en) 2004-10-27 2014-05-13 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators

Also Published As

Publication number Publication date
CA2684450A1 (en) 2008-10-30
CY1117586T1 (el) 2017-04-26
HRP20160689T1 (hr) 2016-07-15
PL2148681T3 (pl) 2016-09-30
JP5804654B2 (ja) 2015-11-04
HUE029397T2 (en) 2017-03-28
US20150051180A9 (en) 2015-02-19
US20140100208A1 (en) 2014-04-10
WO2008129396A3 (en) 2009-08-13
CA2684450C (en) 2017-05-30
EP2148681B1 (en) 2016-03-16
DK2148681T3 (en) 2016-07-04
EP2148681A2 (en) 2010-02-03
ES2575554T3 (es) 2016-06-29
US20100190758A1 (en) 2010-07-29
US8569274B2 (en) 2013-10-29
JP5785392B2 (ja) 2015-09-30
WO2008129396A2 (en) 2008-10-30
JP2010524915A (ja) 2010-07-22
JP2013253098A (ja) 2013-12-19
PT2148681E (pt) 2016-06-17

Similar Documents

Publication Publication Date Title
HRP20160689T1 (hr) Selektivni modulatori progesterona za tretman uterinog krvarenja
HK1223025A1 (zh) 組織閉塞劑
LT2337568T (lt) Minkštųjų audinių inžinierijos būdai ir priemonės
ZA201204267B (en) Nestorone/ estradiol transdermal gel
EP2146643A4 (en) SURGICAL RETRACTOR WITH PADDED
EP2124958A4 (en) TREATMENT OF IL DR SYNDROME BY EMPLOYING TESTOSTERONE AND PROGESTAGEN
HK1136975A1 (zh) 用於防止早產的孕酮
SG10201408158SA (en) Composition and methods used during anti-hiv treatment
EP2187957A4 (en) SELECTIVE CYTOPHERESIS DEVICES AND CORRESPONDING METHODS
GB0603481D0 (en) Slow release agent absorbent dressing
EP2250978A4 (en) CERVICAL MASSAGE DEVICE
EP2114377A4 (en) CONTROLLED RELEASE OF ACTIVE SUBSTANCES IN THE SKIN
GB0714440D0 (en) Rupturing device
EP2517007A4 (en) METHOD AND KITS FOR IDENTIFYING SEROTYPES OF HUMAN ADENOVIRES
HRP20181728T1 (hr) Postupci liječenja analne inkontinencije mioblastima
GB0816650D0 (en) Therapeutic bone grwth and regeneration
EP2249849A4 (en) COMBINATION THERAPY WITH ACTINIDIA AND STEROIDS AND USES THEREOF
GB0606921D0 (en) Skin dressing
EP2375994A4 (en) STYPTIC DEVICE
EP2327407A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR FUNCTIONAL DISORDERS OF THE DIGESTIVE TUBE
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
ZA200904913B (en) Use of VEGF in the treatment of retarded fetal growth in pregnancy
GB2438373B (en) Uterine dilators set
GB2450368B (en) Hemorrhoid treatment device
EP2285328A4 (en) DEVICE FOR TREATING HEMORRHOIDS